Issue link: https://viewer.e-digitaledition.com/i/205083
speCial CliniCal seCtion: GASTRoeNTeRoloGY L–R: Lawrence J. Brandt, mD, maCG, aGa-F, FaSGE, Professor of medicine and Surgery at albert Einstein College of medicine, Emeritus Chief of Gastroenterology at montefiore medical Center, and allan W. Wolkoff, mD, Chief of the Division of Gastroenterology and Liver Diseases and Director of the marion Bessin Liver Research Center at montefiore medical Center and albert Einstein College of medicine Montefiore Medical Center: Pioneering Bacterial Therapy By michael Ferguson an innovative transplantation proCedUre May be the key to stavinG off antibiotiC-resistant sUper bUGs, sUCh as infeCtions CaUsed by ClostridiUM diffiCile (C. diff). iN SePTeMBeR 2013, THe Centers for Disease Control 16 | Lower Hudson/Bronx MD News ■ MDNeWS.CoM PhOtOS © DOn DEmPSEy, WhitE LiGht PhOtOGRaPhy and Prevention (CDC) warned of an increased threat from antibiotic-resistant superbugs. C. diff annually causes a quarter of a million hospitalizations and has earned the CDC's "urgent" threat level. People at the greatest risk for C. diff infection are those taking antibiotics. For the most part, these antibiotics do not predispose to C. diff infection. Other risk factors — such as a compromised immune system, hospitalization and being older than 65 — add to infection risk. Antibiotic use can stimulate the organism to change into a drug-resistant form and also kill many of the intestinal bacteria that keep C. diff from being able to establish a foothold in the intestine (colon), notes Lawrence J. Brandt, MD, MACG, AGA-F, FASGE, Professor of Medicine and Surgery at Albert Einstein College of Medicine, Emeritus Chief of Gastroenterology at Montefiore Medical Center. "We have antibiotics that are known to kill C. Diff," Dr. Brandt says. "The problem is that the organism is very hardy and can survive for long periods outside the body. When the organism is stressed — by being treated with antibiotics — it converts from vegetative to spore form, and this allows it to survive in very hostile conditions. This organism is endemic and ubiquitous. People are easily exposed to it." In 2000, the CDC identified a new, antibiotic-resistant strain of C. diff, and between 2000 and 2007, deaths related to the infection rose 400 percent, obviating the need for a new method to treat the infection. In 1998, prior to the outbreak of the more powerful C. diff, Dr. Brandt began performing fecal microbiota transplants (FMTs) on patients suffering from recurrent C. diff infection, as well as other GI conditions. Since that time, studies have associated the therapy with 90 percent or greater cure rates for patients with recurrent C. diff infection.

